This article first appeared on GuruFocus.
Release Date: May 15, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
Syensqo SA (SHBBF) delivered net sales of EUR1.4 billion with an underlying EBITDA of EUR251 million, marking a 6% sequential increase.
The company secured a new multi-year agreement with Boeing, reinforcing its position in the aerospace sector.
Syensqo SA (SHBBF) completed the sale of its oil and gas business, generating net proceeds of approximately EUR130 million.
The company has implemented pricing actions to offset increased costs due to the Middle East conflict, maintaining its gross margin at 32%.
Syensqo SA (SHBBF) reduced its capital expenditure by 44% year-on-year, demonstrating disciplined capital deployment and improved cash flow management.
Negative Points
The ongoing conflict in the Middle East has led to increased energy costs, logistics complexity, and higher raw material prices, impacting global markets.
Despite improvements, the company’s performance is not yet at its full potential, with challenges in specialty polymers and electronics.
Syensqo SA (SHBBF) experienced a 13% year-on-year decline in underlying EBITDA, primarily due to lower performance in specialty polymers.
The company faces uneven demand and regional divergence in the coatings segment, affecting its performance and care division.
Syensqo SA (SHBBF) has a modest exposure to data centers, which limits its growth potential in this expanding market.
Q & A Highlights
Q: How has the competitive landscape changed recently, particularly in relation to NovCare and specialty polymers? Have you noticed any reduced import pressure? A: (CEO, Mike Rodosic) We have not seen any material impact from changes in the competitive dynamics in NovCare or specialty polymers. Our assumption is that there will be limited impact on product volumes from the Middle East, and we are leveraging our diversified supplier base to mitigate higher costs through pricing actions.
Q: Can you explain the synergies between specialty polymers and the composite division, particularly regarding the cross-selling of pre-PEG materials? A: (President of Composite Materials, Rodrigo Elizondo) Composite Materials has dedicated commercial teams, but there are synergies beyond commercial activities, such as in thermoplastic composites for energy applications. We have common customers, raw materials integration, and complementary expertise, which bring benefits beyond commercial activities.
Story Continues
Q: Can you provide more detail on the improving order book and what is driving the expected growth in Q2? A: (CFO, Christopher Davis) Our Q1 EBITDA is expected to be the low point of the year. We have seen improving order trends and a gradual volume recovery, particularly in composite materials and the electronics sector within specialty polymers. We expect stronger growth through the year, with volume improvements in materials and specialty polymers, especially in electronics and automotive applications.
Q: What is your pricing strategy, especially in the automotive sector, and are you considering similar strategies across the business? A: (CEO, Mike Rodosic) In the automotive sector, we have made deliberate price-volume trade-offs in a competitive market, which supported higher volumes and market share gains. Across the rest of the materials segment, we continue to price for value, with selective adjustments in healthcare to protect volumes.
Q: Can you provide more detail on the semiconductor business and its potential growth, especially regarding inventories and data centers? A: (CEO, Mike Rodosic) Approximately 8% of our group sales in 2025 were related to electronics, with 70% linked to semiconductor applications. Conditions are normalizing, and we expect a progressive recovery through the year. Our exposure to data centers is modest, but we see long-term growth potential driven by AI and connectivity.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.